A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, 6-Week Study Designed to Investigate the Effects of BDP HFA Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal (HPA) Axis When Administered in Adolescent and Adult Subjects (12 to 45 Years of Age) With Perennial Allergic Rhinitis (PAR)

Trial Profile

A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, 6-Week Study Designed to Investigate the Effects of BDP HFA Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal (HPA) Axis When Administered in Adolescent and Adult Subjects (12 to 45 Years of Age) With Perennial Allergic Rhinitis (PAR)

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2013

At a glance

  • Drugs Beclometasone (Primary) ; Prednisone
  • Indications Perennial allergic rhinitis
  • Focus Adverse reactions; Registrational
  • Most Recent Events

    • 03 Jul 2012 Actual patient number changed from 139 to 107 as reported by ClinicalTrials.gov.
    • 03 Jul 2012 Official title amended as reported by ClinicalTrials.gov.
    • 05 Mar 2012 A subgroup analysis was reported at the 2012 American Academy of Allergy, Asthma and Immunology (AAAAI) Meeting, according to a Teva Pharmaceutical Industries media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top